Treatment of Sarcoidosis

Clinical Reviews in Allergy and Immunology

Volumn 49, Issue 1, 2015, Pages 79-92

  Baughman, Robert P ^a   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Infliximab; Methotrexate; Prednisone; Pulmonary sarcoidosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOTROPIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; MEPREDNISONE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; ISOXAZOLE DERIVATIVE; MYCOPHENOLATE MOFETIL;

ARTICLE; ASPERGILLOSIS; BLOOD CELL COUNT; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; COUGHING; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EYE PAIN; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; KIDNEY CALCIFICATION; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; LUNG SARCOIDOSIS; MAINTENANCE THERAPY; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SARCOIDOSIS; SKIN DEFECT; THORAX RADIOGRAPHY; TREATMENT DURATION; VISUAL IMPAIRMENT; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; DRUG EFFECTS; GRANULOMA; IMMUNOLOGY; LUNG; LUNG FUNCTION TEST; PATHOLOGY; RADIOGRAPHY; SKIN;

ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; GRANULOMA; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; ISOXAZOLES; LUNG; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS; SKIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84937638718     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-015-8492-9     Document Type: Article

References (151)

1. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager HJ, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ et al (2001) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889
2. Loddenkemper R, Kloppenborg A, Schoenfeld N, Grosser H, Costabel U (1998) Clinical findings in 715 patients with newly detected pulmonary sarcoidosis—results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis 15:178–182
3. Judson MA, Boan AD, Lackland DT (2012) The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 29:119–127
4. Yeager H, Rossman MD, Baughman RP, Teirstein AS, Judson MA, Rabin DL, Iannuzzi MC, Rose C, Bresnitz EA, DePalo L et al (2005) Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 22:147–153
5. Medical Research Council. Committee on research on chronic bronchitis 1966. Instructions for use of the questionnaire on respiratory symptoms. WJ Holdman, Devon, UK.
6. Baughman RP, Drent M, Culver DA, Grutters JC, Handa T, Humbert M, Judson MA, Lower EE, Mana J, Pereira CA et al (2012) Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 29:90–98
7. Baughman RP, Nunes H, Sweiss NJ, Lower EE (2013) Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 41:1424–1438
8. Sharma OP, Colp C, Williams MH Jr (1966) Course of pulmonary sarcoidosis with and without corticosteroid therapy as determined by pulmonary function studies. Am J Med 41:541–551
9. Vorselaars AD, Wuyts WA, Vorselaars VM, Zanen P, Deneer VH, Veltkamp M, Thomeer M, Van Moorsel CH, and Grutters JC(2013) Methotrexate versus azathioprine in second line therapy of sarcoidosis. Chest. 10–1728.
10. Lower EE, Baughman RP (1995) Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 155:846–851
11. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC (2008) 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 25:143–149
12. Wijnen PA, Cremers JP, Nelemans PJ, Erckens RJ, Hoitsma E, Jansen TL, Bekers O, Drent M (2014) Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 43:1730–1739
13. Pietinalho A, Lindholm A, Haahtela T, Tukiainen P, Selroos O (1996) Inhaled budesonide for treatment of pulmonary sarcoidosis. Results of a double-blind, placebo-controlled, multicentre study. Eur Respir J 9(suppl 23):406s
14. Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England. Br Med J 4:1165–1172
15. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, Harrison BD (1996) British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 51:238–247
16. Baughman RP, Drent M, Kavuru MS, Judson MA, Costabel U, du Bois RM, Albera C, Brutsche M, Davis G, Donahue JF, et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J Respir Crit Care Medin press.
17. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller WJ, Sands BE (2006) A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23:201–208
18. Walsh SL, Wells AU, Sverzellati N, Keir GJ, Calandriello L, Antoniou KM, Copley SJ, Devaraj A, Maher TM, Renzoni E et al (2014) An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2:123–130
19. Keir G, Wells AU (2010) Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med 31:409–418
20. Judson MA, Baughman RP, Costabel U, Mack M, Barnathan ES (2014) The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med 108:189–194
21. Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U (2003) Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 124:1526–1532
22. Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S et al (2009) Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 136:526–535
23. Muers MF, Middleton WG, Gibson GJ, Prescott RJ, Mitchell DN, Connolly CK, Harrison BD (1997) A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment. Sarcoidosis Vasc Diffuse Lung Dis 14:46–56
24. Zappala CJ, Desai SR, Copley SJ, Spagnolo R, Cramer D, Sen D, Alam SM, du Bois RM, Hansell DM, Wells AU (2011) Optimal scoring of serial change on chest radiography in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 28:130–138
25. McKinzie BP, Bullington WM, Mazur JE, Judson MA (2010) Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 339:1–4
26. Drent M, de Vries J, Lenters M, Lamers RJ, Rothkranz-Kos S, Wouters EF, Dieijen-Visser MP, Verschakelen JA (2003) Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 13:2462–2471
27. Hennebicque AS, Nunes H, Brillet PY, Moulahi H, Valeyre D, Brauner MW (2005) CT findings in severe thoracic sarcoidosis. Eur Radiol 15:23–30
28. Hansell DM, Milne DG, Wilsher ML, Wells AU (1998) Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology 209:697–704
29. Abehsera M, Valeyre D, Grenier P, Jaillet H, Battesti JP, Brauner MW (2000) Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 174:1751–1757
30. Mostard RL, Van Kuijk SM, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Drent M (2012) A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis. BMC Pulm Med 12:57. doi:10.1186/1471-2466-12-57
31. Keijsers RG, Verzijlbergen EJ, van den Bosch JM, Zanen P, van de Garde EM, Oyen WJ, Grutters JC (2011) 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 28:123–129
32. Mostard RL, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Voo S, and Drent M (2012) Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 10
33. Vorselaars AD, Verwoerd A, Van Moorsel CH, Keijsers RG, Rijkers GT, and Grutters JC (2013) Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J in press.
34. Baughman RP, Fernandez M, Bosken CH, Mantil J, Hurtubise P (1984) Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting response to therapy. Am Rev Respir Dis 129:676–681
35. DeRemee RA, Rohrbach MS (1980) Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med 92:361–365
36. Lieberman J, Nosal A, Schlessner A, Sastre-Foken A (1979) Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis 120:329–335
37. Baughman RP, Ploysongsang Y, Roberts RD, Srivastava L (1983) Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis 128:631–633
38. Gronhagen-Riska C, Selroos O, Niemisto M (1980) Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis 61:113–122
39. Gronhagen-Riska C, Selroos O (1979) Angiotensin converting enzyme. IV. Changes in serum activity and in lysozyme concentrations as indicators of the course of untreated sarcoidosis. Scand J Respir Dis 60:337–344
40. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J (1997) Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 156:1586–1592
41. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Du BR, Albera C, Brutsche M, Davis G, Donohue JF et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795–802
42. Baughman RP, Judson MA, Lower EE, Highland K, Kwor S, Craft N, Engel PJ (2009) Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 26:110–120
43. Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R (2007) Validity of the Saint George’s Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) 46:296–301
44. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS (2010) The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 104:296–304
45. Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS (2013) The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status. Thorax 68:57–65
46. Victorson DE, Cella D, Grund H, and Judson MA (2013) A conceptual model of health-related quality of life in sarcoidosis. Qual Life Res
47. Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, Barnathan ES (2008) Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 9:155–161
48. Stagaki E, Mountford WK, Lackland DT, Judson MA (2009) The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 135:468–476
49. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A (2005) Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128:1062–1067
50. Baughman RP, Winget DB, Lower EE (2000) Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17:60–66
51. Baughman RP, Lower EE (1997) Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 14:121–130
52. Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JB, Culver DA, Hamzeh NY, et al (2014) Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J.erj00009-erj02014.
53. Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon RC, Winget DB, Judson MA (2002) Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19:198–204
54. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group (1999) Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest 116:424–431
55. Israel HL (1970) The treatment of sarcoidosis. Postgrad Med J 46:537–540
56. James DG, Carstairs LS, Trowell J, Sharma OP (1967) Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet 2:526–528
57. Selroos O, Sellergren TL (1979) Corticosteroid therapy of pulmonary sarcoidosis. Scand J Respir Dis 60:215–221
58. Spratling L, Tenholder MF, Underwood GH, Feaster BL, Requa RK (1985) Daily vs alternate day prednisone therapy for stage II sarcoidosis. Chest 88:687–690
59. Harkleroad LE, Young RL, Savage PJ, Jenkins DW, Lordon RE (1982) Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest 82:84–87
60. Johns CJ, Michele TM (1999) The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins Hospital. Medicine 78:65–111
61. Alberts C, van der Mark TW, Jansen HM, Dutch Study Group on Pulmonary Sarcoidosis (1995) Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Eur Respir J 8:682–688
62. Milman N, Graudal N, Grode G, Munch E (1994) No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 236:285–290
63. du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA (1999) Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 13:1345–1350
64. Zych D, Pawlicka L, Zielinski J (1993) Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 10:56–61
65. Selroos O, Lofroos AB, Pietinalho A, Niemisto M, Riska H (1994) Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 11:126–131
66. Miller MA, BASS HE (1952) Effect of Acthar-c (ACTH) in sarcoidosis. Ann Intern Med 37:776–784
67. Sones M, Israel HL, Dratman MB, Frank JH (1951) Effect of cortisone in sarcoidosis. N Engl J Med 244:209–213
68. Paramothayan S, Jones PW (2002) Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 287:1301–1307
69. Judson MA (1999) An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 115:1158–1165
70. Israel HL, Fouts DW, Beggs RA (1973) A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 107:609–614
71. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H (1997) Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 111:623–631
72. Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, Schwartz D (1994) Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 149:893–898
73. Rizzato G, Montemurro L, Colombo P (1998) The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis 15:52–58
74. Baughman RP, Judson MA, Teirstein A, Yeager H, Rossman M, Knatterud GL, Thompson B (2006) Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 99:307–315
75. Moller DR (2014) Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Eur Respir J 44:1123–1126
76. Stern BJ (2004) Neurological complications of sarcoidosis. Curr Opin Neurol 17:311–316
77. Pawate S, Moses H, Sriram S (2009) Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 102:449–460
78. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, Du BR, Eklund A, Kitaichi M, Lynch J, Rizzato G et al (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16:149–173
79. Hiramitsu S, Morimoto S, Uemura A, Kato Y, Kimura K, Ohtsuki M, Kato S, Sugiura A, Miyagishima K, Hishida H et al (2005) National survey on status of steroid therapy for cardiac sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis 22:210–213
80. Baughman RP, Lower EE (2007) Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 25:334–340
81. Nozaki K, Judson MA (2013) Neurosarcoidosis. Curr Treat Options Neurol 15:492–504
82. Wallaert B, Ramon P, Fournier EC, Hatron PY, Muir JF, Tonnel AB, Voisin C (1986) High-dose methylprednisolone pulse therapy in sarcoidosis. Eur J Respir Dis 68:256–262
83. Khatri KA, Chotzen VA, Burrall BA (1995) Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 131:617–618
84. Lee SY, Lee HG, Kim DS, Kim JG, Chung H, Yoon YH (2009) Ocular sarcoidosis in a Korean population. J Korean Med Sci 24:413–419
85. Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11:478–483
86. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group (2002) Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 121:24–31
87. Ross AP, Ben-Zacharia A, Harris C, Smrtka J (2013) Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol 4:21. doi:10.3389/fneur.2013.00021, eCollection;%2013.:21
88. Gong R (2011) The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 8:122–128
89. Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, Leung N, Reich H, Fervenza FC (2014) A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant 29:1570–1577
90. Barney JB, Baughman RP, O’Hare L, and Lower EE (2014) Clinical experience with Acthar gel in refractory sarcoidosis. Presented at World Association for Sarcoidosis and Other Granulomatous Disease
91. Vucinic VM (2002) What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 8:470–476
92. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U (1999) Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 14:1117–1122
93. Sharma OP, Hughes DTD, James DG, Naish P (1971) Immunosuppressive therapy with azathioprine in sarcoidosis. In: Levinsky L, Macholoa F (eds) Fifth International Conference on Sarcoidosis and Other Granulomatous Disorders. Universita Karlova, Prague, pp 635–637
94. Lewis SJ, Ainslie GM, Bateman ED (1999) Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16:87–92
95. Sahoo DH, Bandyopadhyay D, Xu M, Pearson K, Parambil JG, Lazar CA, Chapman JT, Culver DA (2011) Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 38:1145–1150
96. Brill AK, Ott SR, Geiser T (2013) Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration 86:376–383
97. Hamzeh N, Voelker A, Forssen A, Gottschall EB, Rose C, Mroz P, and Maier LA (2014) Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 10
98. Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, Strek M, Caligiuri P, Machado RF, Niewold TB et al (2014) Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31:46–54
99. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, and Drent M (2011) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol
100. Milman, N., N. Graudal, A. Loft, J. Mortensen, J. Larsen, and B. Baslund (2011) Effect of the TNFalpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J.10-699X.
101. Kamphuis LS, Lam-Tse WK, Dik WA, van Daele PL, van Biezen P, Kwekkeboom DJ, Kuijpers RW, Hooijkaas H, van Laar JA, Bastiaans J et al (2011) Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 184:1214–1216
102. Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JG, Perkins D, Finn PW, Baughman RP (2014) Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 43:1525–1528
103. Park MK, Fontana JR, Babaali H, Gilbert-McClain LI, Joo J, Moss J, Mangeniello VC (2009) Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 26:121–131
104. Zabel P, Entzian P, Dalhoff K, Schlaak M (1997) Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 155:1665–1669
105. Schutt AC, Bullington WM, Judson MA (2010) Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 104:717–723
106. Cremers JP, Drent M, Bast A, Shigemitsu H, Baughman RP, Valeyre D, Sweiss NJ, and Jansen TL (2013) Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med
107. Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL Jr (2003) Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med 163:615–620
108. Lower EE, Broderick JP, Brott TG, Baughman RP (1997) Diagnosis and management of neurologic sarcoidosis. Arch Intern Med 157:1864–1868
109. Dev S, McCallum RM, Jaffe GJ (1999) Methotrexate for sarcoid-associated panuveitis. Ophthalmology 106:111–118
110. Baughman RP, Lower EE (2004) Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 21:43–48
111. Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB et al (2012) Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 142:e1S–e111S
112. Kho LK, Kermode AG (2007) Leflunomide-induced peripheral neuropathy. J Clin Neurosci 14:179–181
113. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U (1999) Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 14:1117–1122
114. Agbogu BN, Stern BJ, Sewell C, Yang G (1995) Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 52:875–879
115. Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters GB III, Thorne JE (2008) Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115:1826–1832
116. Moravan M, Segal BM (2009) Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 72:337–340
117. Drent M, Cremers JP, Jansen TL, Baughman RP (2014) Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31:91–107
118. Sodhi M, Pearson K, White ES, Culver DA (2009) Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 103:268–273
119. Baughman RP, Lower EE, Ingledue R, Kaufman AH (2012) Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 29:26–33
120. Doty JD, Mazur JE, Judson MA (2005) Treatment of sarcoidosis with infliximab. Chest 127:1064–1071
121. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP (2006) Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 100:2053–2059
122. Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, Strek M, Caligiuri P, Machado RF, Niewold TB et al (2014) Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31:46–54
123. Khanna D, Liebling MR, Louie JS (2003) Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 30:1864–1867
124. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, Schroeder DR (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177–185
125. Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41(Suppl 3):S199–S203, S199-S203
126. Baughman RP (2007) Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Rev Port Pneumol 13:S47–S50
127. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D’Haens G, Li J, Rosenfeld MR, Kent JD et al (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 19(146):829–838
128. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B et al (2007) Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 56:1232–1239
129. Panselinas E, Rodgers JK, Judson MA (2009) Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 14:522–528
130. Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JG, Perkins D, Finn PW, Baughman RP (2014) Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 43:1525–1528
131. Lower EE, Baughman RP, Kaufman AH (2012) Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 6:1613–1618
132. Bomprezzi R, Pati S, Chansakul C, Vollmer T (2010) A case of neurosarcoidosis successfully treated with rituximab. Neurology 75:568–570
133. McDonald V, Leandro M (2009) Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 146:233–246
134. Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25–32
135. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I (2007) Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48:1307–1312
136. Baughman RP, Nunes H (2012) Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 8:95–103
137. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129:174–181
138. Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon R, Winget DB, Judson MA (2002) Use of fluticasone for acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19:198–204
139. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 99:1984–1989
140. Baughman RP, Lower EE (2013) Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med 107:2009–2013
141. Chambellan A, Turbie P, Nunes H, Brauner M, Battesti JP, Valeyre D (2005) Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest 127:472–481
142. Denning DW, Pleuvry A, Cole DC (2013) Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 41:621–626
143. Pena TA, Soubani AO, Samavati L (2011) Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 189:167–172
144. Kravitz JN, Berry MW, Schabel SI, Judson MA (2013) A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest 143:1414–1421
145. Nunes H, Uzunhan Y, Freynet O, Humbert M, Brillet PY, Kambouchner M, Valeyre D (2012) Pulmonary hypertension complicating sarcoidosis. Presse Med 41:e303–e316
146. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML (2005) Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128:1483–1489
147. Baughman RP, Engel PJ, Taylor L, Lower EE (2010) Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 138:1078–1085
148. Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG (2013) Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 111:278–285
149. Barnett CF, Bonura EJ, Nathan SD, Ahmad S, Shlobin OA, Osei K, Zaiman AL, Hassoun PM, Moller DR, Barnett SD et al (2009) Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience. Chest 135:1455–1461
150. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, Engel PJ (2014) Bosentan for sarcoidosis associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 145:810–817
151. Baughman RP, Drent M, Culver DA, Grutters JC, Handa T, Humbert M, Judson MA, Lower EE, Mana J, Pereira CA et al (2012) Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis, in press. Ref Type: Generic